Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT00065182 Completed - Clinical trials for Non-Small-Cell Lung Cancer

Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

Start date: August 14, 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.

NCT ID: NCT00063388 Completed - Clinical trials for Non-Small-Cell Lung Cancer

Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer

Start date: May 2003
Phase: Phase 2
Study type: Interventional

Determine tumor response rate and time to disease progression, survival and safety in total populations.

NCT ID: NCT00063154 Completed - Clinical trials for Non-small Cell Lung Cancer

Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy

Start date: July 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.

NCT ID: NCT00062907 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Start date: May 2003
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with early stage non-small cell lung cancer. The vaccine regimen will consist of two fixed doses of recombinant DNA (pVAX/L523S) followed by two doses of recombinant adenovirus (Ad/L523S). The trial will evaluate the dose escalation of Ad/L523S through three cohorts of patients.

NCT ID: NCT00051974 Completed - Clinical trials for Non-Small Cell Lung Cancer

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Start date: December 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.

NCT ID: NCT00050973 Completed - Clinical trials for Non-small Cell Lung Cancer

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Start date: n/a
Phase: Phase 3
Study type: Interventional

This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.

NCT ID: NCT00050960 Completed - Clinical trials for Non-small Cell Lung Cancer

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Start date: May 2002
Phase: Phase 3
Study type: Interventional

This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.

NCT ID: NCT00050674 Completed - Clinical trials for Non-small Cell Lung Cancer

Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma

Start date: November 2001
Phase: Phase 2
Study type: Interventional

Determine whether patients have a decreased incidence of grade 3 and grade 4 neutropenia when Filgrastim-SD/01 is given with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.

NCT ID: NCT00049998 Completed - Clinical trials for Non-Small-Cell Lung Cancer

Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer

Start date: October 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (NSCLC).

NCT ID: NCT00048087 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

Start date: August 2002
Phase: Phase 2
Study type: Interventional

Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy. A course of therapy is 4 weeks. Patients will not receive docetaxel during week 4. A maximum of 8 full cycles of docetaxel plus Iressa are planned. Patients may continue on daily Iressa until progressive disease and/or unacceptable toxicity.